FDA grants three priority vouchers to psychedelics

Following up on President Donald Trump’s April 18th executive order, the US FDA has issued three more Commissioner’s National Priority Vouchers, all to companies working on psychedelics.

The announcement from FDA, which dropped Friday afternoon, doesn’t name the three recipients, but Endpoints has identified them as Compass Pathways, Transcend Therapeutics (currently being acquired by Otsuka Therapeutics) and the Usona Institute. At press time, only Compass Pathways has confirmed its participation, issuing a press release. All three companies have previously received Breakthrough Therapy…